The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

Supportive Care in Cancer

Volumn 24, Issue 3, 2016, Pages 1097-1105

  Innominato, Pasquale F ^a,f   Lim, Andrew S ^b   Palesh, Oxana ^c   Clemons, Mark ^d   Trudeau, Maureen ^e   Eisen, Andrea ^e   Wang, Cathy ^e   Kiss, Alex ^b   Pritchard, Kathleen I ^e   Bjarnason, Georg A ^e  

^a INSERM   (France)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Actigraphy; Breast cancer; Circadian; Clock genes; Melatonin; Quality of life; Sleep

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; HYDROCORTISONE; MELATONIN; PER2 PROTEIN; TRANSCRIPTION FACTOR ARNTL; TRASTUZUMAB; CENTRAL DEPRESSANT AGENT;

ACTIMETRY; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BEDTIME DOSAGE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER PATIENT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COGNITIVE FUNCTION TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; MALE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QLQ C30 QUESTIONNAIRE; QUALITY OF LIFE; SLEEP QUALITY; SOCIAL INTERACTION; TREATMENT DURATION; BREAST NEOPLASMS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FATIGUE; MIDDLE AGED; PROCEDURES; SLEEP;

ACTIGRAPHY; ADULT; AGED; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; FATIGUE; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SLEEP;

EID: 84955715934     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2883-6     Document Type: Article

References (45)

1. Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, Heckler C, Purnell JQ, Janelsins MC, Morrow GR (2010) Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 28(2):292–298
2. Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA (2009) Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther 8(4):361–370
3. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 100(16):1155–1166
4. Mohawk JA, Green CB, Takahashi JS (2012) Central and peripheral circadian clocks in mammals. Annu Rev Neurosci 35:445–462
5. Bass J (2012) Circadian topology of metabolism. Nature 491(7424):348–356
6. Scheer FA, Hilton MF, Mantzoros CS, Shea SA (2009) Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 106(11):4453–4458
7. Innominato PF, Levi FA, Bjarnason GA (2010) Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 62(9–10):979–1001
8. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES (2005) Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 41(13):2023–2032
9. Bonde JP, Hansen J, Kolstad HA, Mikkelsen S, Olsen JH, Blask DE, Harma M, Kjuus H, de Koning HJ, Olsen J, Moller M, Schernhammer ES, Stevens RG, Akerstedt T (2012) Work at night and breast cancer—report on evidence-based options for preventive actions. Scand J Work Environ Health 38(4):380–390
10. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, Claustrat B, Hastings MH, Levi F (2002) Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94(9):690–697
11. Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111(1):41–50
12. Li JC, Xu F (1997) Influences of light–dark shifting on the immune system, tumor growth and life span of rats, mice and fruit flies as well as on the counteraction of melatonin. Biol Signals 6(2):77–89
13. Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, Dimsdale J, Cohen-Zion M, Fiorentino L (2006) Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14(3):201–209
14. Sephton S, Spiegel D (2003) Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17(5):321–328
15. Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Levi FA (2012) Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 131(11):2684–2692
16. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Levi F, Bjarnason GA (2009) Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 69(11):4700–4707
17. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D (2000) Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92(12):994–1000
18. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L (2012) Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 7(8), e42324
19. Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, Spiegel D, Salmon P (2013) Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun 30:S163–170
20. Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK (2015) Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology 53:256–267
21. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA (2014) The circadian timing system in clinical oncology. Ann Med 46(4):191–207
22. Waterhouse J, Reilly T, Atkinson G, Edwards B (2007) Jet lag: trends and coping strategies. Lancet 369(9567):1117–1129
23. Mazzoccoli G, Carughi S, De Cata A, La Viola M, Vendemiale G (2005) Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit 11(6):CR284–288
24. Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, Rogatko A, Xu Z, Harris WB (2008) Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol 26(15):2464–2472
25. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35(12):1688–1692
26. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP (2003) The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26(3):342–392
27. Lim AS, Yu L, Costa MD, Buchman AS, Bennett DA, Leurgans SE, Saper CB (2011) Quantification of the fragmentation of rest-activity patterns in elderly individuals using a state transition analysis. Sleep 34(11):1569–1581
28. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Matteson S, Rakita D, Andrews PL (2002) Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 10(4):329–336
29. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Levi F (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6(8):3038–3045
30. Witting W, Kwa IH, Eikelenboom P, Mirmiran M, Swaab DF (1990) Alterations in the circadian rest-activity rhythm in aging and Alzheimer’s disease. Biol Psychiatry 27(6):563–572
31. Pati AK, Parganiha A, Kar A, Soni R, Roy S, Choudhary V (2007) Alterations of the characteristics of the circadian rest-activity rhythm of cancer in-patients. Chronobiol Int 24(6):1179–1197
32. Lim AS, Chang AM, Shulman JM, Raj T, Chibnik LB, Cain SW, Rothamel K, Benoist C, Myers AJ, Czeisler CA, Buchman AS, Bennett DA, Duffy JF, Saper CB, De Jager PL (2012) A common polymorphism near PER1 and the timing of human behavioral rhythms. Ann Neurol 72(3):324–334.
33. Mormont MC, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F (1998) Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 78(4):421–424
34. James FO, Boivin DB, Charbonneau S, Belanger V, Cermakian N (2007) Expression of clock genes in human peripheral blood mononuclear cells throughout the sleep/wake and circadian cycles. Chronobiol Int 24(6):1009–1034
35. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144
36. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, Zhang W, Chen K (2011) The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat 127(2):531–540
37. Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ (2009) Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117(2):423–431
38. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, Mao JH, Balmain A (2010) Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 28(23):3770–3778
39. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E (2013) Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 31(10):1271–1276
40. Fayers PM (2001) Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer 37(11):1331–1334
41. Ligibel JA (2011) Role of adjuvant and posttreatment exercise programs in breast health. J Natl Compr Canc Netw 9(2):251–256
42. Van Reeth O, Sturis J, Byrne MM, Blackman JD, L’Hermite-Baleriaux M, Leproult R, Oliner C, Refetoff S, Turek FW, Van Cauter E (1994) Nocturnal exercise phase delays circadian rhythms of melatonin and thyrotropin secretion in normal men. Am J Physiol 266(6 Pt 1):E964–974
43. Buxton OM, Frank SA, L’Hermite-Baleriaux M, Leproult R, Turek FW, Van Cauter E (1997) Roles of intensity and duration of nocturnal exercise in causing phase delays of human circadian rhythms. Am J Physiol 273(3 Pt 1):E536–542
44. Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S (2012) The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep 35(2):237–245
45. Savard J, Liu L, Natarajan L, Rissling MB, Neikrug AB, He F, Dimsdale JE, Mills PJ, Parker BA, Sadler GR, Ancoli-Israel S (2009) Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 32(9):1155–1160.